Anticorps Monoclonal anti-SARS-CoV-2 S protein (RBD, 319-541 aa)

SARS-CoV-2 S protein (RBD, 319-541 aa) Monoclonal Antibody for Neutralization, WB, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Virus et plus (2)

Applications

WB, Neutralization, ELISA

Conjugaison

Non conjugué

Publications

8

CloneNo.

1H3E9

N° de cat : 67758-1-Ig

Synonymes

COVID-19 RBD, RBD, SARS-CoV-2 Spike Glycoprotein (319-541 aa), spike protein

---

Galerie de données de validation

• 

  WB analysis of Recombinant protein using 67758-1-Ig

  Recombinant spike protein (RBD domain) were subjected to SDS PAGE followed by western blot with 67758-1-lg (SARS-CoV-2 Spike Glycoprotein (319-541 aa) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

• 

  Neutralization experiment of SARS-CoV-2 S protein (319-541 aa) using 67758-1-Ig

  Surrogate virus neutralization test of SARS-CoV-2 Spike Glycoprotein (319-541 aa) monoclonal antibody 67758-1-Ig using commercial kit. Briefly, RBD protein has been pre-coated on microplate, HRP labeled ACE2 protein and serial dose of 67758-1-Ig are added to the plate simultaneously and incubated for 1 hour at 37°C. The plate was then washed and signal was developed by adding chromogenic substrate followed by stop buffer. Signal strength was monitored at absorbance of 450nm. The IC50 is around 20 μg/mL. Please note that different IC50 will be obtained if different assays are used. Lyophilized format of this product is available.

---

Applications testées

• Résultats positifs en WB: Ag30688,
• Résultats positifs en Neutralization: Protéine recombinante,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• NEUTRALIZATION: NEUTRALIZATION : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 6 publications below

Informations sur le produit

67758-1-Ig cible SARS-CoV-2 S protein (RBD, 319-541 aa) dans les applications de WB, Neutralization, ELISA et montre une réactivité avec des échantillons Virus

• Réactivité: Virus
• Réactivité citée: Humain, souris
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: SARS-CoV-2 S protein (RBD, 319-541 aa) Protéine recombinante Ag30688
• Nom complet: SARS-CoV-2 Spike Protein
• Masse moléculaire calculée: 141 kDa
• Numéro d’acquisition GenBank: NC_045512
• Symbole du gène: COVID-19 S Protein
• Identification du gène (NCBI): 43740568
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, including respiratory, enteric, renal, and neurological diseases. CoV uses its spike protein to recognize ACE2 as its receptors and mediate membrane fusion and virus entry into host cells(PMID: 32221306). Each monomer of trimeric S protein is about 180 kDa, and contains two subunits, S1 and S2,S1 recognizes and binds to host receptors, and subsequent conformational changes in S2 facilitate fusion between the viral envelope and the host cell membrane(PMID: 19198616). Although the amino acid sequences of the S-glycoprotein were found to be different between the various HCoV, the structures showed high similarity, but the best 3D structural overlap shared by SARS-CoV and SARS-CoV-2, consistent with the shared ACE2 predicted receptor (PMID: 32522207). The spike protein of CoVs can be a target for vaccine and therapeutic development (PMID: 19198616).

Lyophilized format of this product is available.

Publications

Species	Application	Title
human	WB	Acta Pharm Sin B; A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants; Authors - Shugang Qin
		J Med Virol; A novel three-plasmid packaging system for chimeric SFV/SIN VRPs derived from Semliki Forest virus and Sindbis virus as a candidate gene delivery vector; Authors - Yonghui Huang
human	WB	Biochem Pharmacol; Harringtonine: A more effective antagonist for Omicron variant; Authors - Shiling Hu
human	WB	Mol Genet Genomics; Optimization of mammalian expression vector by cis-regulatory element combinations; Authors - Lu-Yu Zhou
human	WB	Adv Healthc Mater; Black Phosphorus Nanosheets Assist Nanoerythrosomes for Efficient Mrna Vaccine Delivery and Immune Activation; Authors - Lixin Yang
mouse	WB	Microbiol Spectr; Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice; Authors - Jian Liu